Veru announces meta-analysis presentation at ObesityWeek on enobosarm

Veru (VERU) announced data from a meta-analysis presentation at ObesityWeek, which took place November 5, 2024, in San Antonio, Texas. Conclusions: Meta-analysis shows in older subjects with obesity that enobosarm 3mg daily treatment resulted in DEXA body composition changes of greater total weight loss by day 147 with preservation of lean mass and greater loss of fat. These data support the potential for enobosarm when combined with a GLP-1 RA to also preserve muscle, while preferentially reducing fat resulting in a higher quality weight loss in patients with obesity.